Open

Epcoritamab in Previously Treated WM

The purpose of this study is to determine if epcoritamab can be used to treat patients with previously treated WM.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

This study involves questionnaires, medical history, physical exam, and performance status, tumor assessment, pregnancy test, blood tests, EKG, bone marrow biopsy and aspirate, imaging scans, and study drugs.

Incentives

Study Medication

In-person visits:
0-40+ times

Phone or online visits:
0-40+ times

Total length of participation:
60 months

Looking for Specific Volunteers

Able to participate:

You have lymphoplasmacytic lymphoma/WM
You had at least one prior line of treatment discontinued either due to intolerance or disease progression
You have received prior therapy of an anti-CD20 antibody (e.g. rituximab) and a BTK inhibitor

Not eligible if:

Your disease has transformed to aggressive lymphoma
You are receiving any other investigational agent
You have known or suspected central nervous system involvement or leptomeningeal disease

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Comprehensive Cancer Center
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Christopher Dittus
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Lymphoma)

IRB Number

25-1029

ClinicalTrials.gov

NCT06510491

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.